Serum pentraxin-3, vaspin, apelin ve troponinin dekompanze kalp yetersizliği hastalarındaki seviyeleri

Yıl 2020, 2020 Özel Sayı, 39 - 46, 26.02.2020

Bedri Caner Kaya , Recep Demirbağ

https://doi.org/10.18663/tjcl.635524

Öz

Amaç: Vaspin,
apelinve Pentraxin-3 (PTX-3),kardiyovasküler fonksiyonların, sıvı hemostazının,
vasküler oluşumun, hücre proliferasyonunun, glukoz metabolizmasının ve inflamasyonun
düzenlenmesinde etkili olduğu gösterilmiş biyomarkerlardır. Bu çalışmanın amacı,
dekompanse kalp yetersizliği (KY) hastalarında bu biyobelirteçlerin düzeylerini
değerlendirmektir.

GereçveYöntemler: Çalışmaya
44 dekompanse KY hastası ve 32 sağlıklı birey, hasta ve control grubu olarak dahil
edildi. Her iki grup için de transtorasik ekokardiyografi ve rutin laboratuvar analizlerinin
yanında serum troponin I, vaspin, apelinve PTX-3 düzeyleri analiz edildi.

Bulgular:
Troponin I ve vaspin hasta grubunda daha yüksekti, apelin hasta grubunda daha düşüktü
(hepsi için, p<0.05). PTX-3 düzeyleri hasta grubunda daha fazlaydı, ancak istatistiksel
olarak anlamlı değildi (p=0.133). Troponin I ve PTX-3 düzeyleri hastaneiçi KY tedavisi
ile anlamlı olarak azaldı (her ikisiiçin de, p<0.05). Vaspin ve apelin düzeyleri
anlamlı bir değişiklik göstermedi (sırasıyla p=0.938, p=0.121). Vaspin troponin
ile bağımsız bir ilişkiye sahipti, apelinin PTX-3 ile bağımsız bir ilişkisi vardı,
troponin veapelin vaspin ile bağımsız bir ilişkisi vardı ve son olarak troponin,
PTX-3 ve vaspin dekompanse KY hastalarında apelin ile bağımsız bir ilişkiye sahipti.

Sonuç:
Troponin I ve vaspin düzeyleri dekompanse KY hastalarında daha yüksekti serum
apelin düzeyleri daha düşüktü. PTX-3 düzeyleri KY hastalarında daha yüksekti,
ancak istatistiksel olarak anlamlı değildi. KY hastalarında vaspin ve apelin düzeyleri
KY stabilizasyonu ile değişmedi, ancak troponin I ve PTX-3 düzeyleri anlamlı olarak
azaldı.

Anahtar Kelimeler

troponin I, vaspin, apelin, pentraxin-3, biobelirteç, dekompanse kalp yetersizliği

Serum levels of Pentraxin-3, Vaspin, Apelin and troponin in decompensated heart failure patients

Öz

Aim:
The aim of the present study is to evaluate the levels of these biomarkers in
decompensated heart failure (HF) patients.

Material and Methods:
44
decompensated HF patients and 32 healthy individuals were enrolled in the study
as patient and control groups. Transthoracic echocardiography and serum
troponin I, vaspin, apelin, and PTX-3 levels besides routine laboratory
analysis were performed for both groups.

Results: Troponin
I and vaspin were higher, apelin was lower in patient group (for all,
p<0.05).PTX-3 levels were higher in patient group, but it was not
statistically significant (p=0.133). Troponin I and PTX-3 levels were
significantly decreased (for both, p<0.05) with in-hospital-HF treatment. Vaspinand
apelin levels did not show any significant change (p=0.938, p=0.121,
respectively). Vaspin had an independent relationship with troponin, apelin had an independent relationship with PTX-3,
troponin and apelin had independent relationship with vaspin, and finally
troponin,PTX-3, and vaspin had independent relationship with apelin in
decompensated HF patients.

Conclusion: Troponin I and vaspin levels were elevated,and serum apelin
levels were reduced in decompensated HF patients. PTX-3 levels were higher in
HF patients, but it was not statistically significant. Vaspin and apelin levels
did not change with HF stabilization in HF patients, but troponin I and PTX-3
levels were significantly decreased.t

Anahtar Kelimeler

troponin I, vaspin, apelin, pentraxin-3, biomarker, decompensated heart failure

Kaynakça

• 1. Nishio Y, Sato Y, Taniguchi R, Shituza S, Doi T, Morimoto T et al. Cardiac troponin T vs other biochemical markers in patients with congestive heart failure. Circ J 2007; 71:631-35.
• 2. Peacock WF 4th, De Marco T, Fonarow GC, Diercks D, Wynne J, Apple FS et al; ADHERE Investigators. Cardiac troponin and outcome in acute heart failure. N Engl J Med 2008; 358: 2117-26.
• 3. Maisel A. Understanding B-type natriuretic peptide and its role in diagnosis and monitoring congestive heart failure. Clin Cornerstone 2005; 7:7-17.
• 4. Matsubara J, Sugiyama S, Nozaki T, Sugamura K, Konishi M, Ohba K et al. Pentraxin 3 is a new inflammatory marker correlated with left ventricular diastolic dysfunction and heart failure with normal ejection fraction. J Am CollCardiol 2011; 57:861-9.
• 5. Falcão-Pires I, Leite-Moreira AF. Apelin: a novel neurohumoral modulator of the cardiovascular system. Pathophysiologic importance and potential use as a therapeutic target. Rev Port Cardiol 2005; 24:1263-76.
• 6. Kobat MA, Celik A, Balin M, Altas Y, Baydas A, Bulut M et al. The investigation of serum vaspin level in atherosclerotic coronary artery disease. J Clin Med Res 2012; 4:110-3.
• 7. McMurray JJ, Adamopoulos S, Anker SD, Auricchio A, Bo hm M, Dickstein K et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail 2012; 14: 803-69.
• 8. Yancy CW, Jessup M, Bozkurt B, Butler J, Casey Jr DE, Drazner MH et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am CollCardiol 2013; 62:147-239.
• 9. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972; 18: 499-502.
• 10. Nakagomi A, Seino Y, Endoh Y, Kusama Y, Atarashi H, Mizuno K. Upregulation of monocyte proinflammatory cytokine production by C-reactive protein is significantly related to ongoing myocardialdamage and future cardiac events in patients with chronic heart failure. J Card Fail 2010; 16: 562-71.
• 11. Hudson MP, O’Connor CM, Gattis WA, Tasissa G, Hasselblad V, Holleman CM et al. Implications of elevated cardiac troponin T in ambulatory patients with heart failure: a prospective analysis. Am Heart J 2004; 147: 546-52.
• 12. Jolly SS, Shenkman H, Brieger D, Fox KA, Yan AT, Eagle KA et al. Quantitative troponin and death, cardiogenic shock, cardiac arrest and new heart failure in patients with non-ST-segment elevation acute coronary syndromes (NSTE ACS): insights from the Global Registry of Acute Coronary Events. Heart 2011; 97:197-202.
• 13. Koller L, Kleber M, Goliasch G, Sulzgruber P, Scharnagl H, Silbernagel G et al. C-reactive protein predicts mortality in patients referred for coronary angiography and symptoms of heart failure with preserved ejection fraction. Eur J Heart Fail 2014; 16:758-66.
• 14. Abernethy A, Raza S, Sun JL, Anstrom KJ, Tracy R, Steiner J et al. Pro-Inflammatory Biomarkers in Stable Versus Acutely Decompensated Heart Failure with Preserved Ejection Fraction.J Am Heart Assoc 2018; 12;7(8).
• 15. Hida K, Wada J, Eguchi J, Zhang H, Baba M, Seida A et al. Visceral adipose tissue-derived serine protease inhibitor: a unique insulin-sensitizing adipocytokine in obesity. Proc Natl AcadSci USA 2005; 102:10610-5.
• 16. Seeger J, Ziegelmeier M, Bachman A, Lössner U, Kratzch J, Blüher M et al. Serum levels of the adipokinevaspin in relation to metabolic and renal parameters. J ClinEndocrinolMetab 2008; 93: 247-51.
• 17. Kawano K, Hirashima T, Mori S, Saitoh Y, Kurosumi M, Natori T. Spontaneous long-term hyperglycemic rat with diabetic complications. Otsuka Long-Evans Tokushima Fatty (OLETF) strain. Diabetes 1992; 41:1422-8.
• 18. Zhang B, Peng W, Li H, Lu Y, Zhuang J, Wang K, et al. Plasma vaspin concentrations are decreased in acute coronary syndrome, but unchanged in patients without coronary lesions. Clinical Biochemistry 2013; 46:1520-25.
• 19. Sun N, Wang H, Wang L. Vaspin alleviates dysfunction of endothelial progenitor cells induced by high glucose via PI3K/Akt/eNOS pathway. Int J ClinExpPathol 2015; 8: 482-89.
• 20. Folino A, Montarolo PG, Samaja M, Rastaldo R. Effects of apelin on the cardiovascular system. Heart Fail Rev 2015; 20: 505-18.
• 21. Chandrasekaran B, Dar O, McDonagh T. The role of apelin in cardiovascular function and heart failure. Eur J Heart Fail 2008; 10: 725-32.
• 22. Goidescu CM, Anton FP, Leucuța DC, Mircea PA, Vida-Simiti LA. Serum level of apelin-13 negatively correlated with NT-pro BNP in heart failure patients. Rev Rom Med Lab 2016; 24: 399-412.
• 23. Dalzell JR, Jackson CE, Chong KS, McDonagh TA, Gardner RS. Do plasma concentrations of apelin predict prognosis in patients with advanced heart failure? Biomarkers Med 2014; 8:807-13.